Formulary Enews


Formulary E-news : Having trouble viewing this e-mail? Click here.	You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe from this list.

RESOURCE CENTERS

TOP SEARCHES: Metabolic syndrome // Exenatide // H1N1

•	FDA Safe Use Initiative
•	Antibiotics and birth defects
•	Rare strain of S. Aureus
•	NSAIDs, colorectal cancer
•	Statin use in cardiac patients
•	Statins effective for H1N1

This month we would like to know...

Which of the following best describes your organization's use of manufacturer-generated formulary dossiers as a component of your P&T drug evaluation processes:

a) Require a dossier on most new products and utilize extensively in development of P&T materials

b) Request dossiers periodically and utilize only selective components in development of P&T materials

c) Use dossiers only as a backup reference tool to support internal P&T monograph development processes

d) Rarely request dossiers

e) Do not utilize dossiers at all

Vote in our survey, and see what other P&T committee members have to say.

Contact Us
Click here to contact a Formulary editor.

Click here to contact a Formulary sales representative.

Click here to learn about direct mail, reprints and classifieds in Formulary.

NOVEMBER 13, 2009

FDA initiative announced to reduce preventable harm from medication
FDA announced the Safe Use Initiative, a program aimed at reducing the likelihood of preventable harm from medication use. More...

Some antibiotics tied to birth defects
Researchers studying the association between birth defects and antibiotics use early in pregnancy—1 month before through the third month—have found a link between common drugs used to treat urinary infections and birth defects. More...

Rare strain of S. Aureus is found to be the deadliest
USA600, a rare strain of drug-resistant Staphylococcus aureus is about 5 times more deadly than other strains, according to a study at Henry Ford Hospital in Detroit. More...

NSAIDs reduce mortality in colorectal cancer
Prediagnosis regular nonsteroidal anti-inflammatory drug (NSAID) use and prolonged duration of NSAID use were independently associated with decreased overall mortality and colorectal cancer (CRC) mortality in women with a first primary invasive CRC, according to a large cohort study. More...

Statins may worsen symptoms in cardiac patients
Statins may have negative effects on some cardiac patients, according to a study presented at CHEST 2009. More...

Statins possibly effective in treating H1N1 flu
Hospitalized patients with the seasonal flu who were taking statins were twice as likely to survive than those who weren't taking the drug. More...

Key Topic Updates

Medication Safety

Specialty pharmacy’s role in REMs, FDA’s new drug safety program

Leukotriene inhibitors associated with neuropsychiatric events

FDA issues early communication about ongoing safety review of orlistat

Drug Pipeline/Clinical Updates

Etravirine associated with severe skin and hypersensitivity reactions

Mycophenolic acid associated with increased risk of pure red cell aplasia

Ticagrelor associated with lower rate of death from vascular causes, MI, and stroke

Regulatory/Legislative

FDA leadership promotes scientific integrity, quality standards

Global health concerns generate new therapies for home and abroad

Healthcare reform to shape drug coverage, costs and R&D

You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.